Avoro News

Avoro Capital Updates

We are pleased to share industry insights and updates on Avoro and our portfolio companies. Please reach out if you would like to learn more.

Allogene Therapeutics Completes a $120 Million Private Financing

SOUTH SAN FRANCISCO, Calif.–BUSINESS WIRE–Allogene Therapeutics, Inc., a clinical-stage biotechnology company pioneering the development of allogeneic CAR T therapies for cancer, today announced it has completed a $120 million private financing of Convertible Notes. Participants in this financing were primarily first-time investors in Allogene. The financing was led by Perceptive Advisors and included Deerfield Management …

Read More

Apellis Pharmaceuticals Announces $60 Million Series E Financing

Funding Will Advance Trials of APL-2 in Paroxysmal Nocturnal Hemoglobinuria LOUISVILLE, KY., August 10, 2017 – Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a platform of novel therapeutic compounds for the treatment of autoimmune diseases, today announced the closing of a $60 million Series E preferred stock financing led by Sectoral Asset Management. New …

Read More

Fennec Announces $7.6 Million Private Placement of Common Shares Led by venBio Select Advisor

Fennec Announces $7.6 Million Private Placement of Common Shares Led by venBio Select Advisor RESEARCH TRIANGLE PARK, NORTH CAROLINA — (Marketwired) — 06/08/17 — Fennec Pharmaceuticals Inc. (TSX: FRX)(OTCQB: FENCF) (the “Company” or “Fennec”), a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced chemotherapy ototoxicity in pediatric …

Read More

Corvus Pharmaceuticals Completes $75 Million Series B Financing

Funds will Advance Company’s Immuno-Oncology Small Molecule and Antibody Programs Burlingame, CA, September 29, 2015 – Corvus Pharmaceuticals, a private clinical-stage biopharmaceutical company focused on the development of novel agents targeting the immune system to treat patients with cancer, today announced that it closed a $75 million Series B financing. The transaction was led by …

Read More

Oncobiologics Secures $31 Million Financing

Releasefaa9345b-168e-47b5-8d3e-2b4b4a581492_2150864.pdf Cranbury, NJ – July 27, 2015 — Oncobiologics, Inc.,announced the closing of a $31 million financing. Proceeds will be used to support continued development and expansion of the company’s proprietary BioSymphony™ biosimilar platform and advancement of its preclinical and clinical programs. The investment round was led by new investor, Perceptive Advisors. Participating new investors …

Read More